Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Animal Models

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Animal Model: Rat Antimitotic Agent – MAM or AraC
Preparation Type: Developmental Preparations
DA-related behavior: Enhanced response to amphetamine and MK-801 (post-puberty)
Gating: Disrupted PPI (post-puberty)
Cognitive behavior: Learning deficits in Morris water maze, object recognition, and attentional set-shifting; no change in 5-choice serial reaction time task
Social behavior: Decreased social interaction (deficit present prior to puberty)
Molecular/morphological signature: Reduced hippocampal volume; alterations of NMDAR protein levels and function in the hippocampus; increased neuron density in prefrontal cortex; enhanced NAc DA release to amphetamine; increased firing of dopaminergic neurons; enlarged lateral and third ventricles
Response to APD: Increased response to MK-801 was attenuated by risperidone, haloperidol, and clozapine
Citations: Gourevitch R, Rocher C, Le Pen G, Krebs MO, Jay TM. Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol . 2004 Jul 1 ; 15(4):287-92. Abstract

Flagstad P, Mørk A, Glenthøj BY, van Beek J, Michael-Titus AT, Didriksen M. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology . 2004 Nov 1 ; 29(11):2052-64. Abstract

Elmer GI, Sydnor J, Guard H, Hercher E, Vogel MW. Altered prepulse inhibition in rats treated prenatally with the antimitotic Ara-C: an animal model for sensorimotor gating deficits in schizophrenia. Psychopharmacology (Berl) . 2004 Jul 1 ; 174(2):177-89. Abstract

Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry . 2006 Aug 1 ; 60(3):253-64. Abstract

Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology . 2007 Feb 1 ; 32(2):483-92. Abstract

Le Pen G, Jay TM, Krebs MO. Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. J Psychopharmacol . 2011 Jun ; 25(6):822-35. Abstract

Chin CL, Curzon P, Schwartz AJ, O'Connor EM, Rueter LE, Fox GB, Day M, Basso AM. Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse . 2011 May ; 65(5):393-403. Abstract

Hradetzky E, Sanderson TM, Tsang TM, Sherwood JL, Fitzjohn SM, Lakics V, Malik N, Schoeffmann S, O'Neill MJ, Cheng TM, Harris LW, Rahmoune H, Guest PC, Sher E, Collingridge GL, Holmes E, Tricklebank MD, Bahn S. The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. Neuropsychopharmacology . 2012 Jan ; 37(2):364-77. Abstract


April 24, 2014
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark

Check out our Schizophrenia Bulletin Forum Discussion: Prefrontal Inefficiency Is Associated With Polygenic Risk for Schizophrenia.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright